NCT01262586View on ClinicalTrials.gov

Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.

PHASE3CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Type II Diabetes Mellitus
Interventions
DRUG

Vildagliptin

DRUG

Glimepiride

Trial Locations (1)

Unknown

Novartis Investigative Site, Mainz

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY